albumin binding comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
| Property | Value | Notes |
|---|---|---|
| Molar mass | approximately 4813 Da | calculated from the 39-residue sequence |
| Appearance | white to off-white powder | typical of lyophilised peptide material |
| Solubility class | freely soluble in water | measured value depends on salt form and pH |
| Plasma protein binding | >99 percent | linked to the fatty diacid side chain |
| Class | dual GIP and GLP-1 receptor agonist | receptor activity varies with the assay used |
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Alfatradiol, also known as 17α-estradiol and sold under the brand names Avicis, Avixis, Ell-Cranell Alpha, and Pantostin, is a weak estrogen and 5α-reductase inhibitor medication which is used topically in the treatment of pattern hair loss (androgenic alopecia or pattern baldness) in men and women. It is a stereoisomer of the endogenous steroid hormone and estrogen 17β-estradiol (or simply estradiol).
=== Water vascular system === The water vascular system of the starfish is a hydraulic system made up of a network of fluid-filled canals and is concerned with locomotion, adhesion, food manipulation and gas exchange. Water enters the system through the madreporite, a porous, often conspicuous, sieve-like ossicle on the aboral surface. It is linked through a calcareous-lined canal called the stone canal, to a ring canal around the mouth opening. A set of radial canals branch off from the ring canal; one radial canal runs along the ambulacral groove in each arm. There are short lateral canals branching off alternately to either side of the radial canal, each ending in an ampulla. These bulb-shaped organs are joined to tube feet (podia) on the exterior of the animal by short linking canals that pass through ossicles in the ambulacral groove. There are usually two rows of tube feet but in some species, the lateral canals are alternately long and short and there appear to be four rows. The interior of the whole canal system is lined with cilia. Water is pushed into the tube face when longitudinal muscles in the ampullae contract, and shut the valves in the lateral canals. This causes the tube feet to stretch and touch the substrate. Although the tube feet resemble suction cups in appearance, the gripping action is a function of adhesive chemicals rather than suction. Other chemicals and relaxation of the ampullae allow for release from the substrate. The tube feet latch on to surfaces and move in a wave, with one arm section attaching to the surface as another releases.
On April 9, 2008, the Councils of the Cherokee Nation and the Eastern Band of Cherokee Indians at the Joint Council Meeting held in Catoosa, Oklahoma, passed a resolution: "Opposing Fabricated Cherokee 'Tribes' and 'Indians'". It denounced further state or federal recognition of so-called Cherokee tribes or bands. These tribes committed to exposing and assisting state and federal authorities in eradicating any group that attempts or claims to operate as a government of the Cherokee people. The resolution asked that no public funding from any federal or state government should be expended on behalf of non-federally recognized Cherokee tribes or bands. The Nation stated it would call for a full accounting of all federal monies given to state-recognized, unrecognized or 501(c)(3) charitable organizations that claimed any Cherokee affiliation. It called for federal and state governments to stringently apply a federal definition of "Indian", to include citizens of federally recognized Indian tribes, to prevent non-Indians from selling membership in so-called Cherokee tribes for the purpose of exploiting the Indian Arts and Crafts Act of 1990. In a controversial segment that could affect Cherokee Baptist churches and charitable organizations, the resolution stated that no 501(c)(3) organization, state recognized, or unrecognized groups shall be acknowledged as Cherokee. The resolution challenged celebrities who claim Cherokee ancestry (Examples are in the "List of self-identified Cherokees".)
Sources: en.wikipedia.org
=== Blue Shift === On February 16, 2021, HECU Collective announced that they would be taking a break from their mod Black Mesa: Azure Sheep and were now focusing on a remake of Half-Life: Blue Shift. Unlike another remake in progress, Guard Duty by Tripmine Studios, the mod utilizes assets from Black Mesa instead of creating it from scratch and is released in chapters. The mod began development after a previous attempt at a Blue Shift remake, Insecurity, was abandoned. Half of the members transitioned to working on the mod while the other half continued work on Azure Sheep. The first of the game's eight chapters was released on March 16, 2021, and as of November 2024, five of the eight total chapters have been released.
Certain serotonergic psychedelics and related non-hallucinogenic drugs, acting as serotonin 5-HT2A receptor agonists, have been reported to have mild stimulant and/or "psychic energizing" (i.e., acute antidepressant) effects, both in animals and humans. These effects are often present at low or sub-hallucinogenic doses. Psychedelics are also known to promote wakefulness or cause insomnia. Psychedelic and related drugs that have been reported to produce stimulant effects include the phenethylamines 2,5-DMA (DOH), DOM, DOET, DOPR, DON, MTFEM, Ariadne (4C-DOM; BL-3912; Dimoxamine), 2C-B, 2C-D, 2C-G-N, and ASR-2001 (2CB-5PrO), and the tryptamines 5-MeO-DiPT and 5-MeO-MiPT, among others. The lysergamide LSD has also been reported to have mild stimulant effects. Conversely, psilocybin does not seem to produce the same stimulant effects. The non-hallucinogenic Ariadne was under development as a potential pharmaceutical drug to take advantage of such effects in the treatment of conditions like depression in the 1970s, and reached phase 3 clinical trials for such indications, but was shelved reportedly for strategic economic reasons. ASR-2001, which is likewise non-hallucinogenic, is under development for use as a stimulant-like medication for treatment of psychiatric disorders. Serotonin 5-HT2A receptor agonists have been found to increase dopamine levels in brain areas like the frontal cortex, striatum, and nucleus accumbens in animal studies.
== Marriage and family == Dayhoff's husband was Edward S. Dayhoff, an experimental physicist who worked with magnetic resonance and with lasers. They had two daughters who are also academics, Ruth and Judith. Judith Dayhoff has a PhD in mathematical biophysics from the University of Pennsylvania and is the author of Neural network architectures: An introduction and coauthor of Neural Networks and Pattern Recognition. Ruth Dayhoff graduated summa cum laude in Mathematics from the University of Maryland and focused on Medical Informatics while doing her MD at Georgetown University School of Medicine. During medical school, she co-authored a paper and a chapter in The Atlas of Protein Sequence and Structure with her mother, describing a new way to measure how closely proteins are related. Her husband Vincent Brannigan is professor emeritus of Law and Technology at the University of Maryland School of Engineering. Ruth was a founding Fellow of the American College of Medical Informatics. She pioneered the integration of Medical Imaging and invented the Vista Imaging System. She was chosen for the National Library of Medicine's project on the 200 women Physicians who "changed the face of medicine." She serves as director of Digital Imaging in Medicine for the United States Department of Veterans Affairs.
Sources: en.wikipedia.org
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.
The fatty diacid side chain promotes strong binding to serum albumin, which slows clearance and yields a half-life of roughly five days. That profile supports once-weekly administration in clinical use.
In vitro assays detect activity at both the GIP and GLP-1 receptors, but the activity ratio depends on the assay system and the signalling pathway measured. The relative contribution of each receptor to clinical effects is still being characterised.
建议在低温、避光、干燥环境中密封保存，常见条件为 2 至 8 摄氏度，长期存放可置于更低温度。应避免反复冻融，并尽量减少容器开启次数。